miR-296-5p、Skp2、RPL6与前列腺癌病理特征的关系及对手术预后的影响

张灿峰, 刘嘉欣, 杨文博

PDF(725 KB)
PDF(725 KB)
重庆医科大学学报 ›› 2025, Vol. 50 ›› Issue (02) : 198-203. DOI: 10.13406/j.cnki.cyxb.003702
泌尿系统疾病

miR-296-5p、Skp2、RPL6与前列腺癌病理特征的关系及对手术预后的影响

作者信息 +

Association of miR-296-5p,S-phase kinase-associated protein 2, and ribosomal protein L6 with the pathological features of prostate cancer and their influence on surgical prognosis

Author information +
History +

摘要

目的 探讨微小RNA-296-5p、S期激酶相关蛋白2(S-phase kinase-associated protein 2,Skp2)、核糖体蛋白L6(ribosomal protein L6,RPL6)与前列腺癌病理特征的关系及对手术预后的影响。 方法 选取2018年1月至2023年1月120例前列腺患者,均行腹腔镜前列腺癌术治疗,对比不同病理特征患者miR-296-5p、Skp2、RPL6 mRNA表达水平,分析各指标与病理特征的关系。根据术后1年是否生化复发分为复发组(n=21)与未复发组(n=97),比较2组临床资料、miR-296-5p、Skp2、RPL6 mRNA表达水平,分析miR-296-5p、Skp2、RPL6对手术预后的影响及预测价值。 结果 不同病理分期、Gleason评分、术前血清前列腺特异性抗原(prostate specific antigen,PSA)水平、淋巴结转移患者miR-296-5p、Skp2、RPL6 mRNA表达水平比较,差异有统计学意义(F=12.927、22.416、10.088、34.239、20.180、12.208,t=4.649、-5.770、-5.713、4.716、-5.647、-6.884,均P=0.000);miR-296-5p与Gleason评分、病理分期、术前血清前列腺特异性抗原(prostate specific antigen,PSA)水平、淋巴结转移呈负相关(r=-0.578、-0.539、-0.517、-0.556,均P<0.001),Skp2、RPL6 mRNA与Gleason评分、病理分期、术前血清PSA水平、淋巴结转移呈正相关(r=0.531、0.507、0.476、0.493、0.494、0.473、0.420、0.505,均P<0.001);复发组淋巴结转移、病理分期、切缘阳性率、Gleason评分、高于未复发组,术后辅助治疗率低于未复发组(P<0.05);复发组miR-296-5p表达水平低于未复发组,Skp2、RPL6 mRNA表达水平高于未复发组(P<0.05);校正前,logistic回归分析,病理分期、Gleason评分、淋巴结转移、切缘阳性、术后辅助治疗、miR-296-5p、Skp2、RPL6 mRNA是前列腺癌患者术后生化复发的影响因素(P<0.05),校正后,miR-296-5p、Skp2、RPL6 mRNA仍是前列腺癌患者术后生化复发的影响因素(P<0.05);miR-296-5p、Skp2、RPL6联合预测前列腺术后生化复发的AUC为0.902(95%CI=0.833~0.949),大于各指标单独预测(P<0.05)。 结论 前列腺癌患者miR-296-5p、Skp2、RPL6表达水平与病理特征、术后复发密切相关,三者联合预测前列腺术后生化复发具有较高的参考价值。

Abstract

Objective To explore the relationship between microRNA-296-5p(miR-296-5p),S-phase kinase-associated protein 2(Skp2),ribosomal protein L6 (RPL6) and pathological characteristics of prostate cancer,as well as their impact on surgical prognosis. Methods A total of 120 patients with prostate cancer who were treated from January 2018 to January 2023 were enrolled,and all patients underwent laparoscopic therapy for prostate cancer. The mRNA expression levels of miR-296-5p,Skp2,and RPL6 were compared between the patients with different pathological features,and the association between each indicator and pathological features was analyzed. According to the presence or absence of recurrence at 1 year after surgery,the patients were divided into recurrence group with 21 patients and non-recurrence group with 97 patients. The two groups were compared in terms of clinical data and the mRNA expression levels of miR-296-5p,Skp2,and RPL6,and the influence of miR-296-5p,Skp2,and RPL6 on surgical prognosis and their predictive value were analyzed. Results There were statistically significant differences in the expression levels of miR-296-5p,Skp2,and RPL6 mRNA among patients with different pathological stages,Gleason scores,preoperative serum prostate specific antigen(PSA) levels,and lymph node metastasis(F=12.927,22.416,10.088,34.239,20.180,12.208;t=4.649,-5.770,-5.713,4.716,-5.647,-6.884;P=0.000 for all). miR-296-5p was negatively correlated with Gleason score,pathological stage,preoperative serum PSA level,and lymph node metastasis(r=-0.578,-0.539,-0.517,-0.556;P<0.001 for all),while Skp2 and RPL6 mRNA were positively correlated with Gleason score,pathological stage,preoperative serum PSA level,and lymph node metastasis(r=0.531,0.507,0.476,0.493,0.494,0.473,0.420,0.505;P<0.001 for all). Compared with the non-recurrence group,the recurrence group had significantly higher lymph node metastasis,pathological stage,rate of positive margin,and Gleason score and a significantly lower rate of postoperative adjuvant therapy(P<0.05). Compared with the non-recurrence group,the recurrence group had a significantly higher expression level of miR-296-5p and significantly lower mRNA expression levels of Skp2 and RPL6(P<0.05). Before correction,the logistic regression analysis showed that pathological stage,Gleason score,lymph node metastasis,positive surgical margin,postoperative adjuvant therapy,and the mRNA expression levels of miR-296-5p,Skp2,and RPL6 mRNA were influencing factors for postoperative biochemical recurrence in patients with prostate cancer(P<0.05),and after correction,the mRNA expression levels of miR-296-5p,Skp2,and RPL6 were still influencing factors for postoperative biochemical recurrence in patients with prostate cancer (P<0.05). The ROC curve analysis showed that the combination of miR-296-5p,Skp2,and RPL6 had an area under the ROC curve of 0.902(95%CI=0.833~0.949) in predicting biochemical recurrence after prostate cancer surgery,with a significantly larger AUC than each indicator alone(P<0.05). Conclusion The expression levels of miR-296-5p,Skp2,and RPL6 are closely associated with pathological features and postoperative recurrence in patients with prostate cancer,and the combination of the three indicators has a high reference value in predicting biochemical recurrence after prostate cancer surgery.

关键词

微小RNA-296-5p / S期激酶相关蛋白2 / 核糖体蛋白L6 / 前列腺癌 / 病理特征 / 手术 / 预后

Key words

microRNA-296-5p / S-phase kinase-associated protein 2 / ribosomal protein L6 / prostate cancer / pathological features / surgery / prognosis

中图分类号

R114

引用本文

导出引用
张灿峰 , 刘嘉欣 , 杨文博. miR-296-5p、Skp2、RPL6与前列腺癌病理特征的关系及对手术预后的影响. 重庆医科大学学报. 2025, 50(02): 198-203 https://doi.org/10.13406/j.cnki.cyxb.003702
Zhang Canfeng, Liu Jiaxin, Yang Wenbo. Association of miR-296-5p,S-phase kinase-associated protein 2, and ribosomal protein L6 with the pathological features of prostate cancer and their influence on surgical prognosis[J]. Journal of Chongqing Medical University. 2025, 50(02): 198-203 https://doi.org/10.13406/j.cnki.cyxb.003702

参考文献

1
Sung H Ferlay J Siegel RL,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin202171(3):209-249.
2
Azal WN Capibaribe DM Dal Col LSB,et al. Incontinence after laparoscopic radical prostatectomy:a reverse systematic review[J]. Int Braz J Urol202248(3):389-396.
3
Ziogou A Giannakodimos A Giannakodimos I. The role of urinary miRNAs in the diagnosis,management and follow- up of prostatic cancer[J]. Microrna202312(2):83-86.
4
Lee KH Lin FC Hsu TI,et al. MicroRNA-296-5p (miR-296-5p) functions as a tumor suppressor in prostate cancer by directly targeting Pin1[J]. Biochim Biophys Acta20141843(9):2055-2066.
5
段松. 前列腺癌组织中Skp2的表达及其与前列腺癌术后复发的关系[J]. 东南国防医药201618(1):47-50.
Duan S. The expression of Skp2 in prostate cancer and its relationship with postoperative recurrence[J]. Mil Med J Southeast Chin201618(1):47-50.
6
孙铭强,张建勇,袁 瑛,等. 前列腺癌患者组织中RPL6的表达及临床意义[J]. 现代生物医学进展201818(4):745-749.
Sun MQ Zhang JY Yuan Y,et al. Prostate cancer:expression and clinical significance of ribosomal protein L6[J]. Prog Mod Biomed201818(4):745-749.
7
中国抗癌协会泌尿男生殖系统肿瘤专业委员会前列腺癌学组. 前列腺癌筛查中国专家共识(2021年版)[J]. 中国癌症杂志202131(5):435-440.
Prostate Cancer Group,Urogenital Cancer Committee,Chinese Anti-Cancer Association. Chinese expert consensus on prostate cancer screening(2021 edition)[J]. Chin Oncol202131(5):435-440.
8
Epstein JI Zelefsky MJ Sjoberg DD,et al. A contemporary prostate cancer grading system:a validated alternative to the gleason score[J]. Eur Urol201669(3):428-435.
9
Mottet N Bellmunt J Bolla M,et al. EAU-ESTRO-SIOG guidelines on prostate cancer. part 1:screening,diagnosis,and local treatment with curative intent[J]. Eur Urol201771(4):618-629.
10
Sekhoacha M Riet K Motloung P,et al. Prostate cancer review:genetics,diagnosis,treatment options,and alternative approaches[J]. Molecules202227(17):5730.
11
Cornford P van den Bergh RCN Briers E,et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. part II-2020 update:treatment of relapsing and metastatic prostate cancer[J]. Eur Urol202179(2):263-282.
12
魏英,蔡维敏,王飞,等. 血清睾酮联合红细胞分布宽度、白蛋白碱性磷酸酶比值对腹腔镜前列腺癌根治术后生化复发的预测价值[J]. 现代生物医学进展202323(4):755-760.
Wei Y Cai WM Wang F,et al. Predictive Value of serum testosterone combined with red blood cell distribution width and albumin alkaline phosphatase ratio for biochemical recurrence after laparoscopic radical prostatectomy[J]. Pro in Mod Bio202323(4):755-760
13
Giannakodimos I. Urinary miRNAs as diagnostic biomarkers for prostatic cancer:current dilemmas and novel potential role for a digital rectal examination[J]. Curr Med Chem202229(25):4311-4313.
14
刘小四,丁凯阳. miR-296-5p在恶性肿瘤中的研究进展[J]. 徐州医科大学学报201737(9):627-630.
Liu XS Ding KY. Research progress of microRNA-296-5p in tumors[J]. J Xuzhou Med Univ201737(9):627-630.
15
Kachuri L Hoffmann TJ Jiang Y,et al. Genetically adjusted PSA levels for prostate cancer screening[J]. Nat Med202329(6):1412-1423.
16
Mokoatle M Mapiye D Marivate V,et al. Discriminatory Gleason grade group signatures of prostate cancer:an application of machine learning methods[J]. PLoS One202217(6):e0267714.
17
于峰,刘先艮,杨帆,等. Circ-0033074靶向miR-296-5p对前列腺癌细胞增殖、侵袭、迁移及凋亡的影响[J]. 中国老年学杂志202343(7):1740-1745.
Yu F Liu XG Yang F,et al. Effects of Circ-0033074 targeting miR-296-5p on proliferation,invasion,migration and apoptosis of prostate cancer cells [J]. Chinese Journal of Gerontology202343(7):1740-1745
18
Rezaeian AH Phan LM Zhou XB,et al. Pharmacological inhibition of the SKP2/p300 signaling axis restricts castration-resistant prostate cancer[J]. Neoplasia202338:100890.
19
Asmamaw MD Zhang LR Liu HM,et al. Skp2 is a novel regulator of LSD1 expression and function in gastric cancer[J]. Genes Dis202310(6):2267-2269.
20
Celada SI Li GL Celada LJ,et al. Lysosome-dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer[J]. Mol Oncol202317(10):2126-2146.
21
Liang H Zhang FM Hong YN,et al. Synergistic silencing of Skp2 by siRNA self-assembled nanoparticles as a therapeutic strategy for advanced prostate cancer[J]. Small202218(14):e2106046.
22
Wang HC Luo CW Chen TY,et al. Skp2-mediated Zeb1 expression facilitates cancer migration by a ubiquitination-independent pathway[J]. Life Sci2022311(Pt A):121135.
23
刘 畅,王庆伟,罗振宇,等. SKP2、kindlin-2在前列腺癌组织中的表达及其与患者临床特征的关系[J]. 癌症进展201917(6):727-730.
Liu C Wang QW Luo ZY,et al. Expression of SKP2 and kindlin-2 in prostate cancer and the relationship with clinical characteristics[J]. Oncol Prog201917(6):727-730.
24
Suzuki M Tezuka K Handa T,et al. Upregulation of ribosome complexes at the blood-brain barrier in Alzheimer’s disease patients[J]. J Cereb Blood Flow Metab202242(11):2134-2150.
25
Zhang J Ma QL Han Y,et al. Downregulated RPL6 inhibits lung cancer cell proliferation and migration and promotes cell apoptosis by regulating the AKT signaling pathway[J]. J Thorac Dis202214(2):507-514.

基金

2023年度河南省医学科技攻关计划资助项目(LHGJ20230885)

评论

PDF(725 KB)

Accesses

Citation

Detail

段落导航
相关文章

/